Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.37 |
| ▸ | SELE | P16581 | 1/20 | 0.37 |
| ▸ | CTPS1 | P17812 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17888567 | 0.84 | OPRK1 (0.39) | ICAM1SELEPARP10 | |
| SCHEMBL17888686 | 0.83 | ICAM1 (0.38) | ICAM1SELEPARP10 | |
| SCHEMBL17899370 | 0.83 | PDE4D (0.39) | ICAM1SELEPARP10 | |
| SCHEMBL17899371 | 0.82 | ICAM1 (0.41) | KDM4ESMN1; SMN2LMNAHPGDMAPT | |
| SCHEMBL17899367 | 0.77 | MAPT (0.48) | KDM4EPOLBALDH1A1GAAL3MBTL1 | |
| SCHEMBL3492009 | 0.75 | PDE4D (0.50) | POLBKMT2ACTPS1PARP1 | |
| SCHEMBL17899157 | 0.74 | PDE4D (0.39) | — | |
| SCHEMBL17888598 | 0.72 | PARP10 (0.38) | KDM4EALDH1A1L3MBTL1SMN1; SMN2MAPT | |
| SCHEMBL17899127 | 0.71 | CHEK2 (0.38) | PARP10 | |
| SCHEMBL17888640 | 0.71 | MAPT (0.49) | KDM4EALDH1A1KMT2ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11013728-B2 | Cyclin-dependent kinase 8 and/or 19 inhibitor | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2021-05-25 | — | — | US | disclosed |
| US-20210100783-A1 | NOVEL CYCLIN-DEPENDENT KINASE 8 AND/OR 19 INHIBITOR | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2021-04-08 | — | — | US | disclosed |
| US-20160207883-A1 | NOVEL AROMATIC COMPOUND AND USE THEREOF | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2016-07-21 | — | — | US | disclosed |
| US-20160207883-A1 | NOVEL AROMATIC COMPOUND AND USE THEREOF | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2016-07-21 | — | — | US | disclosed |
| EP-3040329-A1 | NOVEL AROMATIC COMPOUND AND USE THEREOF | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2016-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207883-A1 | NOVEL AROMATIC COMPOUND AND USE THEREOF | SOST, BMP2, ALPI | KDM4E 954/4885POLB 3402/4885ALDH1A1 2733/4885 |
| US-20210100783-A1 | NOVEL CYCLIN-DEPENDENT KINASE 8 AND/OR 19 INHIBITOR | CCNI, CDK9, CDK8 | KDM4E 730/4885POLB 903/4885ALDH1A1 2793/4885 |
| US-11013728-B2 | Cyclin-dependent kinase 8 and/or 19 inhibitor | CCNI, CDK9, CDKN1A | KDM4E 783/4885POLB 874/4885ALDH1A1 3115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.